Search

Displaying 253 - 264 items out of 300 results
Press release
COMPEL Study Shows Continuing Osimertinib Treatment Through Progression with the Addition of Chemotherapy Improves Progression-Free Survival in EGFR-Mutated NSCLC
… and other thoracic malignancies, attracting nearly 7,000 researchers, physicians, and specialists from more than 100 … will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more …
Press release
Ivonescimab Outperforms Pembrolizumab in Phase 3 Study for First-Line Treatment of PD-L1-Positive Advanced NSCLC In HARMONi-2 Study 
… and other thoracic malignancies, attracting nearly 7,000 researchers, physicians and specialists from more than 100 … will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more …
Press release
IASLC Awards Joseph W. Cullen Prevention/Early Detection Award to William Evans at the World Conference on Lung Cancer
… other thoracic malignancies, attracting more than 7,000 researchers, physicians, and specialists from more than 100 … will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more …
Press release
Crizotinib Fails to Improve Disease-Free Survival in Resected Early-Stage ALK+ NSCLC
… and other thoracic malignancies, attracting nearly 7,000 researchers, physicians, and specialists from more than 100 … covers a wide range of disciplines and unveils several research studies and clinical trial results. For more …
Press release
Tarlatamab with Anti-PD-L1 as First-Line Maintenance After Chemo-Immunotherapy for ES-SCLC Demonstrates Acceptable Safety Profile and Unprecedented Overall Survival
… and other thoracic malignancies, attracting nearly 7,000 researchers, physicians, and specialists from more than 100 … covers a wide range of disciplines and unveils several research studies and clinical trial results. For more …
Press release
Study Discloses Clinical-Relevant Intertumoral Heterogeneity of NSCLCs Driven by MET Exon 14 Skipping
… other thoracic malignancies, attracting more than 7,000 researchers, physicians and specialists from more than 100 … will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more …
Press release
NADIM ADJUVANT Trial Suggests Benefit of Adjuvant Chemo-Immunotherapy in Resected Stage IB–IIIA NSCLC
… and other thoracic malignancies, attracting nearly 7,000 researchers, physicians, and specialists from more than 100 … will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more …
Press release
Iza-Bren in combination with Osimertinib Shows 100% Response Rate in EGFR-Mutated NSCLC, Phase II Study Finds
… and other thoracic malignancies, attracting nearly 7,000 researchers, physicians, and specialists from more than 100 … will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more …
Press release
Patients with Lung Cancer More Likely to Feel Anxiety and Experience Treatment Delays During COVID-19 Pandemic
… other thoracic malignancies, attracting more than 7,000 researchers, physicians and specialists from more than 100 … will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more …
Press release
FLAURA2 Trial Shows Osimertinib Plus Chemotherapy Improves Overall Survival in EGFR-Mutated Advanced NSCLC
… and other thoracic malignancies, attracting nearly 7,000 researchers, physicians, and specialists from more than 100 … covers a wide range of disciplines and unveils several research studies and clinical trial results. For more …
Press release
Ifinatamab Deruxtecan Demonstrates High Response Rate in Previously Treated Extensive-Stage Small Cell Lung Cancer: Phase 2 IDeate-Lung01 Trial
… and other thoracic malignancies, attracting nearly 7,000 researchers, physicians, and specialists from more than 100 … covers a wide range of disciplines and unveils several research studies and clinical trial results. For more …
Press release
Ivonescimab Plus Chemotherapy Improves Progression-Free Survival in Patients with EGFR+ NSCLC Following 3rd-Generation EGFR-TKI Therapy
… and other thoracic malignancies, attracting nearly 7,000 researchers, physicians, and specialists from more than 100 … covers a wide range of disciplines and unveils several research studies and clinical trial results. For more …